

Study to evaluate the safety and efficacy of the Versius surgical system in robot-assisted total hysterectomy (a surgical procedure to remove your womb)

Submission date 27/10/2022	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 03/11/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 28/10/2022	Condition category Surgery	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Minimal access surgery (also known as keyhole surgery) has been carried out for over 30 years at hospitals around the world. It is well established and has several advantages over other surgical methods, such as a shorter recovery time, fewer complications and shorter hospital stay.

Thousands of minimal access operations are carried out each year. Recently it has been possible to use robot arms to help carry out minimally invasive operations.

This study is being run to assess the safety and competence of the Versius® Surgical Robotic System in performing operations for removal of the womb in females. Versius is a robot designed to be used in minimal access surgery. It has been developed and built by CMR Surgical Limited, a UK based and registered company. The system allows a surgeon to stand or sit a console to control a set of robotic arms which are holding instruments needed to perform minimal access surgery.

Who can participate?

All non-pregnant female patients aged 18 years and above, eligible for surgery with Versius, as decided by the operating surgeon.

What does the study involve?

All participants will have womb removal surgery as usual and as decided by their healthcare professionals.

What are the possible benefits and risks of participating?

There are no direct benefits to participants. The information collected may benefit patients in the future. The risks from participating in this study are similar to those associated with any minimal access (keyhole) womb removal surgical procedure.

Where is the study run from?

CMR Surgical (UK)

When is the study starting and how long is it expected to run for?
March 2022 to March 2023

Who is funding the study?
CMR Surgical (UK)

Who is the main contact?
Dr Mark Slack
mark.slack@cmrsurgical.com

Contact information

Type(s)

Principal investigator

Contact name

Dr Rajnish Nagarkar

Contact details

HCG Manavata Cancer Centre
Nashik
Mumbai Naka
Mumbai
India
422002
+91 98230 61929
drraj@manavatacancercentre.com

Type(s)

Scientific

Contact name

Dr Manisha Jadav

Contact details

Navelcar Pride, Ground Floor, Department of Clinical Operations
Kadamba Plateau, NH4A
Chimbel
Tiswadi
Goa
India
403006
+91 96232 43509
manisha.jadhav@cmrsurgical.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CA-00361

Study information

Scientific Title

Prospective clinical study to evaluate the safety and efficacy of the Versius surgical system in robot-assisted total hysterectomy

Acronym

V.C.S.-TLH

Study objectives

The Versius surgical system is safe and efficacious in performing robot-assisted total hysterectomies

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 11/08/2022, Manavata Clinical Research Institute Ethics Committee (Mumbai Naka, Nashik-422002, India; +91 253-6661111; mpec.nashik@gmail.com), ref: ECR/500/Inst/MH/2013-RR20

Study design

Prospective non-randomized single-arm clinical trial cohort

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Robot assisted total hysterectomy

Interventions

A prospective single arm cohort study for robot assisted total hysterectomies, with the Versius Surgical Robotic System. Use of Versius, patient care and all follow-ups (up to day 42 +/-2 days) will be as per standard clinical practice, and GCP and regulatory requirements will be strictly followed.

Intervention Type

Device

Phase

Phase II/III

Drug/device/biological/vaccine name(s)

Versius Surgical Robotic System

Primary outcome(s)

Primary safety outcome:

Incidence of serious adverse events, recorded on the data entry platform at any time between commencement of surgery (intraoperative) to the end of the trial (postoperative, between incidence of surgery to 30 days after surgery)

Primary efficacy outcome:

Rate of successful completion of robot assisted surgery without unplanned conversion to other laparoscopic or open surgery, as recorded on the data entry platform

Key secondary outcome(s)

1. Operative time measured in minutes from incision to skin closure at the facility, collected as procedural data from medical records
2. Estimated blood loss (in ml) during surgery, collected as procedural data from medical records
3. Blood transfusion during surgery (number of blood transfusion products used (if any)) collected from patient's medical records
4. Any intra-operative complications during surgery collected as procedural data and from patient's medical records
5. Return to operating room within 24 hours after surgery, measured using medical records
6. Length of hospital stay in days (from date of procedure to date of discharge), measured using medical records
7. Incidence of readmission to hospital within 30 days after surgery, measured using medical records and at 30-day follow-up
8. Incidence of reoperation within 30 days after surgery, measured using medical records and at 30-day follow-up
9. 30-day mortality from medical records and/or follow-up visit/call during the 30-day follow up
10. Vaginal vault healing, as assessed and recoded by surgeon on medical records at the clinic on 42 days post operative follow up
11. Histopathology results of any surgically removed specimens from medical records available at day of discharge and at 30 day follow up
12. Incidence of device deficiencies and use errors regardless of relationship to an adverse event, collected as procedural and/or adverse event data and from patient medical records
13. All adverse events, including postoperative complications reported using Clavien-Dindo Classification and according to medical records, up to 30 days' follow up
14. Device performance data including unplanned instrument usage, clashes, collision detection, alarms, collected as procedural data during surgery

Completion date

31/03/2023

Eligibility

Key inclusion criteria

1. Patient deemed suitable for total laparoscopic hysterectomy procedure using Versius Surgical Robotic System
2. Patients able to provide written informed consent to participate in the study (with help of appropriate legal representatives if required)
3. Female, aged 18 years or above

4. Female of childbearing potential, must not be pregnant
5. Patients with BMI ≤ 40 kg/m². Ideally BMI ≥ 25 to ≤ 40 kg/m²

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

Female

Key exclusion criteria

1. Patient participation in an investigational clinical study within 30 days before screening
2. Inability or difficulties to provide informed consent
3. Uncontrolled hypertension (\geq Systolic: 180 mmHg/Diastolic: 120 mmHg)
4. Diabetes mellitus (Glycemia > 11 mmol/L; > 200 mg/dL)
5. Oncological cases, patients undergoing surgery or treatment for malignant disease
6. Patients who fall into American Society of Anaesthesiologists (ASA) Class IV or above
7. Uterus size of > 14 weeks
8. History of chronic alcohol or drug abuse
9. Chronic renal failure or on dialysis
10. Significant medical history or immunocompromised
11. Subjects with any other clinically significant unstable medical disorder, lifethreatening disease, or anything else in the opinion of the Investigator which would contra-indicate a surgical procedure
12. Patient tested COVID positive within last 30 days of screening
13. Patient tested COVID positive within 48 hours within procedure

Date of first enrolment

17/11/2022

Date of final enrolment

01/01/2023

Locations**Countries of recruitment**

India

Study participating centre

HCG Manavata Cancer Centre

Behind Shivang auto

Mumbai Naka
Nashik
Maharashtra
Mumbai
India
422002

Sponsor information

Organisation

CMR Surgical (United Kingdom)

ROR

<https://ror.org/00nq5xx94>

Funder(s)

Funder type

Industry

Funder Name

CMR Surgical

Results and Publications

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date.

IPD sharing plan summary

Data sharing statement to be made available at a later date

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Study website	Study website	11/11/2025	11/11/2025	No	Yes